KSC 2019 (´ëÇѽÉÀåÇÐȸ Á¦63Â÷ Ãß°èÇмú´ëȸ) : 2019-10-19±³À°ÀÏÀÚ : 2019-10-19
±³À°Àå¼Ò : ¿öÄ¿Èú È£ÅÚ Art ¿Ü
±³À°ÁÖÁ¦ :
KSC 2019 (´ëÇѽÉÀåÇÐȸ Á¦63Â÷ Ãß°èÇмú´ëȸ)ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
´ã´çÀÚ : Á¶À±ÇÏ
¿¬¶ôó : 02-3275-5258
À̸ÞÀÏ :
herz8@circulation.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 2000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 8 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 120,000¿ø
ºñ°í »çÀüµî·Ï: ±³¼ö ¹× °³¿øÀÇ-100000, ÀüÀÓÀÇ/Àü°øÀÇ/±âŸ-70000ÇöÀåµî·Ï: ±³¼ö ¹× °³¿øÀÇ-120000, ÀüÀÓÀÇ/Àü°øÀÇ/±âŸ-90000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-19 Art 08:40~09:00 Role of Strain Echocardiography Á¶±¸¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-19 Art 09:00~09:20 Role CMR ÃÖ¿¬Çö(¼º±Õ°üÀÇ´ë)
±³À°½Ã°£ 10-19 Art 09:20~09:40 Role of Cardiac CT with FFR ±è¿µÇÐ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10-19 Art 09:40~10:00 Role of Nuclear Imaing °¿øÁØ(¿¬¼¼ÀÇ´ë)
Åä·Ð 10-19 Art 10:00~10:10 Discussion ()
ÈÞ½Ä 10-19 10:10~10:20 Break ()
±³À°½Ã°£ 10-19 Calla 10:20~10:40 Role of Vascular Smooth Cell in the Inflammaging of the Artery Sung Ha Park(Yonsei Univ. Korea)
±³À°½Ã°£ 10-19 Calla 10:40~11:00 Molecular Imaging for Vascular Inflammation and Atherosclerosis Jonathan R. Lindner(Oregon Health & Science Univ. USA)
±³À°½Ã°£ 10-19 Calla 11:00~11:20 Vascular Calcification: Pathogenesis and Clinical Implications Hae-Young Lee(Seoul National Univ. Korea)
±³À°½Ã°£ 10-19 Calla 11:20~11:40 Assessment of Capillary Function in Diabetes and Metabolic Syndrome Jonathan R. Lindner(Oregon Health & Science Univ. USA)
Åä·Ð 10-19 Calla 11:40~11:50 Discussion ()
ÈÞ½Ä 10-19 11:50~12:00 Break ()
±³À°½Ã°£ 10-19 Cosmos 12:00~12:20 Optimal Anti-Hypertensives in CardioMetabolic Diseases with Hypertension ¹Ú»ó¹Î(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 10-19 Cosmos 12:20~12:40 New Paradigm of Combination Therapy for Uncontrolled Hypertensive Patients ÀÌÁÖÈñ(ÃæºÏÀÇ´ë)
±³À°½Ã°£ 10-19 Abstract/Case zone & Moderated Poster zone 12:40~14:00 Case Presentation & Moderated Poster ´Ù°»ç(´Ù¼Ò¼Ó)
±³À°½Ã°£ 10-19 Walker 2 14:00~14:20 Best Coronary Revascularization Strategy in Diabetic Patients ¹Ú´ö¿ì(¿ï»êÀÇ´ë)
±³À°½Ã°£ 10-19 Walker 2 14:20~14:40 Secondary Prevention for Coronary Artery Disease in Diabetic Patients È«¼øÁØ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 10-19 Walker 2 14:40~15:00 From Evidence to Practice: SGLT2 Inhibitors for CV Risk Reduction in Diabetes ÀÓ¼ö(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-19 Walker 2 15:00~15:20 From Evidence to Practice: GLP-1 analogues for CV Risk Reduction in Diabetes ±èº´ÁØ(°¡ÃµÀÇ´ë)
Åä·Ð 10-19 Walker 2 15:20~15:30 Discussion ()
ÈÞ½Ä 10-19 15:30~15:40 Break ()
±³À°½Ã°£ 10-19 Theatre 15:40~15:55 Antithrombotic Therapy in Patients with AF Undergoing PCI: Dual or Triple Therapy? ¹Ú±ÙÈ£(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 10-19 Theatre 15:55~16:10 Antithrombotic Strategy in AF with Stable CAD and PAD Á¤¿µÈÆ(°æ»óÀÇ´ë)
±³À°½Ã°£ 10-19 Theatre 16:10~16:25 Antithrombotic Therapy in Korean Patients with AF and CAD: Where Are We Now? À̼ҷÉ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 10-19 Theatre 16:25~16:40 Periprocedual Management in AF Patients with NOACs: PCI and RFCA À¯ÈñÅÂ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 10-19 Theatre 16:40~16:55 Left Atrial Appendage Occlusion in AF Patient with CAD: Which Patients Would Undergo? ÀÓÈ«ÀÇ(ÇѸ²ÀÇ´ë)
Åä·Ð 10-19 Theatre 16:55~17:10 Discussion ()